We are at a critical time and supporting climate journalism is more important than ever. Science News and our parent organization, the Society for Science, need your help to strengthen ...

are due to its lower affinity for heparin-binding proteins and endothelial cells, shorter fractionated heparin chain (which allows for better bioavailability), and unsaturable renal elimination.

As a highly potent, natural anticoagulant, heparin is well known as an antithrombotic agent, and it has been shown to inhibit smooth muscle cell proliferation. INTERGARD Heparin grafts incorporate ...

After more than 70 years of effective clinical use, heparin remains the most common anticoagulant in use and one of the most commonly prescribed drugs to hospitalized patients. However ...

Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...

Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to ...

By mimicking naturally occurring mast cell-derived heparin proteoglycans, APAC targets arterial injury sites providing long-lasting antithrombotic and anti-inflammatory action in situ. The funding ...